Apricoxib, is an orally active, selective COX-2 inhibitor, used as as an analgesic and anti-inflammatory agent, and also has anticancer potential, since COX-2 inhibition can reduce tumor growth and augment therapy.
This oral COX-2 inhibitor (FW = 356.44 g/mol; CAS 162011-90-7), also
named CS-706 and 4-[2- (4-ethoxyphenyl) -4-methyl-1H-pyrrol-1-yl]-
benzene sulfonamide, targets Cyclooxygenase-2, which is over-
expressed in advanced stage non-small-cell lung cancer (NSCLC), possibly
as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2).
That said, a randomized, double-blind, placebo-controlled, multicenter
phase II study found little evidence of efficacy of apricoxib in
combination with either docetaxel or pemetrexed in patients with
biomarker-selected NSCLC. See also Rofecoxib
